RU2123342C1 - Method of treatment of patients with lung cancer - Google Patents

Abstract

FIELD: medicine, oncology. SUBSTANCE: method involves the use of autolymph in combination with chemopreparations. Initially patient lymph is incubated with cytochrome c and then with chemopreparations and administrated in blood stream of patient. So activated lymph provides the enhancement of antitumor effect, decreases intoxication and improves immunological status of patients. EFFECT: improved method of treatment, enhanced effectiveness. 1 ex

Description

 The invention relates to medicine, in particular, oncology, and can be used in the treatment of locally advanced lung cancer.

Known methods of treating lung cancer (in the book. "Antitumor therapy" / Under the editorship of prof. Translatorova N.I. M. "Medicine", 1986, pp. 45 - 47) by intravenous administration of various combinations of chemotherapeutic agents. For example, an intravenous chemotherapy regimen is used: cyclophosphamide - 500 mg / m ² , adriamycin - 50 mg / m ² , vincristine - 1.4 mg / m ² with a repeated dose of the drug after 4 weeks. A very effective CAM-cyclophosphamide regimen is 1-1.5 g / m ² , adriamycin 60 mg / m ² , methotrexate 30 mg / m ² , intravenously, with a course dose repeated after 3 weeks.

 However, the effectiveness of the use of the above chemotherapy regimens is low, the direct reduction of the tumor does not exceed 25 - 32%. Achieving complete tumor regression is usually not removed. The time interval between the introduction of course doses of chemotherapy is quite long.

A known method of treating lung cancer (see the book. "Unconventional methods for the diagnosis and treatment of cancer patients." - M .: 1990, S. 84 - 95), which consists in the fact that chemotherapy is dissolved in autolymph, incubated at a temperature of 37 ^o C in for 25 to 30 minutes and is administered intravenously to the patient.

 The disadvantage of this method is the small antitumor efficacy, although treatment tolerance is significantly improved. However, in a number of patients, the consequences of the toxic effect of cytostatics are also traced.

 A known method for the treatment of lung cancer (patent N 1806744 from 07.29.93. Bull. N 12 from 30.09.9. Auth. Chubukhchiev TB, Zinkovich SA, Frantsents EM, Kartashov SZ), including the use of antioxidants / tocopherol, retinol, unitiol, ferrum-lek / in the pre- and postoperative period in therapeutic doses with an additional 7-10 sessions of HBO.

 The application of the method leads to the normalization of metabolic processes, protects biological membranes from the damaging effects of hypoxic induction of free radical lipid peroxidation, which leads to the optimization of treatment.

 The disadvantage of this method is that antioxidants are administered intramuscularly, so they do not affect the immunological system of the patient.

 The aim of the invention is to increase the antitumor effect and reduce the toxicity of chemotherapy drugs, increase the immunological status of the patient.

 This goal is achieved by the fact that the patient's autolymph is incubated with cytochrome-C, then with antitumor drugs and injected into the bloodstream of the patient.

 The invention is new, as it is unknown from the level in the field of treatment of locally advanced forms of lung cancer using autolymph.

 The novelty of the proposed invention “A method for the treatment of lung cancer" is that the patient's autolymph is incubated with cytochrome-C, then with antitumor drugs and injected into the bloodstream of the patient.

 The invention has an inventive step, since for an oncologist, it does not explicitly follow from the level of development of medicine in this field of oncology in the treatment of patients with locally advanced forms of lung cancer. Incubation of autolymph with cytochrome-C, that is, stimulation of autolymph and its formed elements, protects biological membranes from the damaging effects of hypoxic induction of free radical lipid peroxidation, normalizes metabolic processes. Further incubation of the resulting mixture with antitumor drugs, unknown in medical practice, leads not only to a decrease in intoxication, but also helps to increase the antitumor effect.

 Therefore, the proposed technical solution cannot be obvious and follow from the level of development in this field of oncology, since it is unknown in the world or in the Russian / CIS / medical literature.

 The invention is industrially applicable, as it can be used in healthcare: oncology dispensaries, research institutes of oncology in the treatment of patients with locally advanced lung cancer.

A method of treating lung cancer is as follows: the patient is drained of the thoracic lymphatic duct, lymph is collected in 5 vials, 200 ml each, containing 0.5 heparin and placed in a refrigerator at a temperature of + 4 ^o C. Then, in turn, in each of vial was added 30 mg cytochrome-C, the resulting mixture was incubated in a thermostat at 37 ^o C for 25 - 30 minutes after which the vials was added 0.2 course dose chemotherapy - cyclophosphamide, doxorubicin, fluorouracil - and again incubated in a thermostat at a sheopisannyh modes. Then the contents of the vial are administered intravenously to the patient. A similar procedure is repeated every other day, a total of 10 days is required for the course of treatment, while a total of about 1.5 course doses of chemotherapy are administered.

 Thus, the "Method for the treatment of lung cancer" consists of two parts: stimulation of autolymph and its proprietary elements by cytochrome-C, followed by the interaction of activated lymph with chemotherapy.

An example of a specific implementation: "Method for the treatment of lung cancer":
Patient G.V.V., 55 years old / and. N 2240 / b / was admitted to the thoracic department of RNII on 06.29.93, with a diagnosis of central cancer of the left lung, art. III gr. II. An X-ray examination /30.06.93/ revealed that the left pulmonary field is inhomogeneously darkened, reduced in volume, the mediastinal organs are pulled to the left.

 With fibrobronchoscopy / July 1, 1993, left at a distance of 2 cm from the root, the distal part of the left main bronchus is sharply narrowed, deformed due to the tumor process. It is impossible to conduct an endoscope distally. Conclusion: cancer of the distal left main bronchus. Cit. N 13549-50 - small cell cancer.

 Due to the prevalence of the process, it was decided to conduct autolymphochemotherapy.

 07/12/93, performed drainage of the thoracic duct, received 2000 ml of lymph.

 07/13/93 started autolymphochemotherapy with cytochrome-C.

 In total for 5 injections the patient received: 5.0 cyclophosphamide, 5.0 - 5-fluorouracil, 150 mg of methotrexate and 150 mg of cytochrome-C. The treatment was completed on July 27, 1993. The patient underwent satisfactory treatment. There were no complications, reactions from the blood side were not observed.

 During the control x-ray examination after 3 weeks, a complete regression of the tumor process was noted.

 The technical result from the use of the “Method for the treatment of lung cancer” is that the stimulation of autolymph and its formed elements by cytochrome-C provides an increase in the antitumor effect, a decrease in toxicity, and an increase in the immunological status of patients.

Claims (1)

 A method of treating lung cancer, including autolymphochemotherapy, characterized in that, in order to increase the antitumor effect and reduce the toxicity of chemotherapy drugs, the patient's autolymph is initially incubated with cytochrome-C, then with chemotherapy and injected into the patient's bloodstream.